Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer | Zendy

Ulka N. Vaishampayan | Zendy; Lance K. Heilbrun | Zendy; Paul Monk | Zendy; Sheela Tejwani | Zendy; Guru Sonpavde | Zendy; Clara Hwang | Zendy; Daryn Smith | Zendy; Pallavi Jasti | Zendy; Kimberlee Dobson | Zendy; Brenda Dickow | Zendy; Elisabeth I. Heath | Zendy; Louie Semaan | Zendy; Michael L. Cher | Zendy; Joseph A. Fontana | Zendy; Sreenivasa R. Chinni | Zendy

Open Access

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

Author(s) -

Ulka N. Vaishampayan,

Lance K. Heilbrun,

Paul Monk,

Sheela Tejwani,

Guru Sonpavde,

Clara Hwang,

Daryn Smith,

Pallavi Jasti,

Kimberlee Dobson,

Brenda Dickow,

Elisabeth I. Heath,

Louie Semaan,

Michael L. Cher,

Joseph A. Fontana,

Sreenivasa R. Chinni

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.34633

Subject(s) - enzalutamide , medicine , bicalutamide , prostate cancer , androgen deprivation therapy , oncology , clinical endpoint , randomized controlled trial , cancer , androgen receptor

Key Points Question Is enzalutamide combined with androgen deprivation therapy associated with better outcomes than treatment with bicalutamide in Black men with metastatic hormone-sensitive prostate cancer (mHSPC)? Findings In a randomized clinical trial of 71 men with mHSPC, the 7-month prostate-specific antigen response rate was significantly improved with enzalutamide vs bicalutamide among Black patients but not among non-Black patients. Meaning These findings suggest that treatment with enzalutamide is associated with improved outcomes vs bicalutamide in Black men with mHSPC, and incorporation of enzalutamide in the mHSPC treatment plan should be strongly considered.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research